MedTrace Logo

Detecting Parkinson's Disease Through Speech Analysis

NCT03133611 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 350

Last updated 2019-08-09

No results posted yet for this study

Summary

Speech is an important indicator of motor function and movement coordination and can be extremely sensitive to involvement in the course of neurologic diseases. The aim of this project is to discover for the first time using simple speech recording and high end pattern analysis preclinical stages of disabling central nervous system disorders including Parkinson's disease and other alpha-synucleinopathies in "at high risk" patients with REM sleep behavior disorder and thus provide one essential prerequisite for trials on REM sleep behavior disorder with preventive therapy.

Conditions

  • Parkinson Disease
  • REM Sleep Behavior Disorder

Interventions

OTHER

Speech assessment

Each subject will undergo short non-invasive speech assessment lasting approximately 15 minutes that will be recorded using microphone.

OTHER

Routine clinical assessment

Volunteers who enroll in the study will undergo various assessments lasting about 2 hours, including neurological examination of both motor and non-motor skills, autonomic testing and cognitive testing.

Sponsors & Collaborators

  • General University Hospital, Prague

    collaborator OTHER

  • University Hospital, Montpellier

    collaborator OTHER

  • Mayo Clinic

    collaborator OTHER

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    collaborator OTHER

  • Medical University Innsbruck

    collaborator OTHER

  • San Raffaele University Hospital, Italy

    collaborator OTHER

  • Philipps University Marburg

    collaborator OTHER

  • Czech Technical University in Prague

    lead OTHER

Principal Investigators

  • Jan Rusz, PhD · Czech Technical University in Prague

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-04-01
Primary Completion
2019-12-31
Completion
2020-12-31

Countries

  • United States
  • Austria
  • Canada
  • Czechia
  • France
  • Germany
  • Italy

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03133611 on ClinicalTrials.gov